Focus:
News
-
24 May 2019
Four pharma firms accused of anti-competitive practices in UK
The UK Competition and Markets Authority (CMA) has accused Alliance Pharmaceuticals, Focus, Lexon and Medreich of avoiding competition for anti-nausea drug, prochlorperazine.
-
24 May 2019
Lilly starts selling half-price version of Humalog insulin
Eli Lilly has announced the market launch of a half-price, generic version of its Humalog insulin.
-
23 May 2019
Chugai Pharmaceutical to build new $1bn research lab in Japan
Chugai Pharmaceutical has revealed plans to establish a core research laboratory at its business site in Yokohama, Kanagawa Prefecture, Japan.
-
23 May 2019
Janssen’s Invokana secures FDA priority review status
Janssen Pharmaceutical has received priority review from the US Food and Drug Administration (FDA) for its Invokana (canagliflozin) medicine in type 2 diabetes (T2D) patients with chronic kidney disease (CKD).
-
23 May 2019
Amgen offers $167m to acquire Nuevolution
Amgen has made a public offer to buy Denmark-based biopharmaceutical company Nuevolution for a cash consideration of around $167m.
-
22 May 2019
ILC Dover’s new Cork manufacturing plant includes 10,500 sq ft of clean room capability
ILC Dover opens new manufacturing facility in Cork, Ireland.
-
22 May 2019
Researchers develop new opioid with faster results and fewer side effects
Researchers at Tulane University, US, have developed a new opioid that works quicker than morphine and other opioid painkillers, and does not produce the same pain sensitivity and addiction.
-
22 May 2019
Mallinckrodt files lawsuit against US health agencies
Mallinckrodt has filed a lawsuit against the US Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) over a decision to change Medicaid rebates for its...
-
22 May 2019
Evotec to acquire biologics company Just Biotherapeutics
Evotec has entered a definitive agreement to acquire Just Biotherapeutics and its in-house drug development technology platform J.DESIGN.
-
22 May 2019
Merck signs $1bn deal to buy Peloton Therapeutics
Merck has signed a definitive agreement to acquire biopharmaceutical company Peloton Therapeutics for an upfront payment of $1.05bn.